NCT07793006|RecruitingDMCFDA Device
Loading search results
Sponsor study identifier
interventional
500
1 country
1
Study Start
March 17, 2025
Actual (reported)Primary Completion
December 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
December 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Persons living with HIV (PLWH) in sub-Saharan Africa (SSA), lymphadenopathy often portends one of a number of life-threatening diseases including tuberculosis, lymphoma, and multicentric Castleman disease (MCD). Overcoming these delays and missed diagnoses requires new approaches to identify lymphoma and MCD.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
March 17, 2025
Actual (reported)July 17, 2026
Actual (reported)August 28, 2026
Actual (reported)December 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
December 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Number of patients with diagnoses
Proportion of patients diagnosed with each of the following by histopathology and immunohistochemistry: tuberculosis, lymphoma, MCD, other diagnosis, or non-diagnostic.
Enrollment
Baseline clinical and laboratory characteristics
Enrollment
Baseline clinical and laboratory characteristics
Enrollment
HIV-infected patients in routine clinical care with unexplained lymphadenopathy
DNA isolation to be tested by nucleic acid amplification using the TINY device
The sample will be eluted into two tubes, one for Gene Xpert testing and one for storage for EBV and KSHV testing by qPCR and TINY.
Lighthouse Trust HIV Centers of Excellence
Lilongwe, Malawi
Michael Painschab, MD
IUSCCC
First Submitted
July 17, 2026
First Posted
August 28, 2026
Study Start
March 17, 2025
Actual (reported)Primary Completion
December 2028
EstimatedOngoing Dynamic Choice to Address HIV Treatment Interruption in Malawi
Baseline clinical and laboratory characteristics
Enrollment
Baseline clinical and laboratory characteristics
Enrollment
Baseline clinical and laboratory characteristics
Enrollment
Tiny Isothermal Nucleic acid Amplification System (TINY)
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Planned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
December 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
August 28, 2026
Record last verified: 2026-08
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: